Eylea (aflibercept) is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). In people with a certain type of eye disease, new blood vessels grow under the retina where they leak blood and fluid. This is known as the "wet form" of macular degeneration.
Eylea is used to treat wet age-related macular degeneration. It is also used to treat swelling in the retina caused by a blockage in the blood vessels.
Eylea is also used to treat diabetic retinopathy, an eye disorder in diabetics that can lead to a buildup of fluid in the retina and cause blindness.
The recommended dose for EYLEA is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.
Important Injection Instructions
For ophthalmic intravitreal injection. EYLEA must only be administered by a qualified physician.
Pre-filled Syringe: A 30-gauge × ½-inch sterile injection needle is needed but not provided.
Vial: A 5-micron sterile filter needle (19-gauge × 1½-inch), a 1-mL Luer lock syringe and a 30-gauge × ½-inch sterile injection needle are needed.
EYLEA is available packaged as follows:
Vial Kit with Injection Components (filter needle, syringe, injection needle)